Cancer Chemotherapy and Pharmacology

, Volume 72, Issue 2, pp 305–314

Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis

  • Zhi Peng
  • Qianqian Wang
  • Jing Gao
  • Zhaoning Ji
  • Jiajia Yuan
  • Ye Tian
  • Lin Shen
Original Article

DOI: 10.1007/s00280-013-2194-x

Cite this article as:
Peng, Z., Wang, Q., Gao, J. et al. Cancer Chemother Pharmacol (2013) 72: 305. doi:10.1007/s00280-013-2194-x

Abstract

Background and aims

The association between glutathione-S-transferase P1 (GSTP1) Ile105Val polymorphism and oxaliplatin-induced neuropathy has been investigated in a number of published studies. However, most of these studies were based on small sample sizes and the results remained inconsistent. To assess the relationship between GSTP1 gene Ile105Val polymorphism and its susceptibility to oxaliplatin-induced neuropathy, a meta-analysis of previous studies was conducted.

Methods

Two investigators independently searched studies published up to December 2012 from the databases of PubMed, EMBASE and The Cochrane Library. The pooled effect was calculated as odds ratio (OR) and corresponding 95 % confidence intervals (CIs) using fixed-effect or random-effect model.

Results

Twelve prospective trials and two retrospective clinical trials involving 2,191 participants met the inclusion criteria. Combined analyses of these studies showed no significant associations between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy, yielding OR of 1.08 (95 %CI 0.67–1.74, P = 0.754) in dominant model. Similar results were also obtained in recessive model (OR = 1.67, 95 %CI 0.56–4.93, P = 0.357) and allelic analysis (OR = 1.22, 95 %CI 0.67–2.24, P = 0.513). Since significant heterogeneity across studies, the pooled effects were calculated by random-effect model. No evidence of publication biases was identified in this meta-analysis.

Conclusion

This meta-analysis did not support the hypothesis that GSTP1 Ile105Val polymorphism was related to the occurrence of neurotoxicity in oxaliplatin-treated patients. Given the limited number of studies and potential bias, large-scale and well-designed clinical trials should be needed to confirm these hypotheses.

Keywords

GSTP1 Polymorphism Neuropathy Meta-analysis 

Supplementary material

280_2013_2194_MOESM1_ESM.docx (444 kb)
Supplementary material 1 (DOCX 443 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Zhi Peng
    • 1
    • 3
  • Qianqian Wang
    • 2
  • Jing Gao
    • 1
  • Zhaoning Ji
    • 3
  • Jiajia Yuan
    • 1
  • Ye Tian
    • 1
  • Lin Shen
    • 1
  1. 1.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal OncologyPeking University Cancer Hospital and InstituteBeijingChina
  2. 2.Department of Epidemiology, Beijing Institute of Traumatology and OrthopaedicsBeijingChina
  3. 3.Department of Medical Oncology, Yijishan HospitalWannan Medical CollegeWuhuChina